38 Result(s)
within
Walter Stummer
Oncology
-
Article
Open AccessCorrection to: Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status
-
Article
Open AccessMaximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status
Maximal cardiopulmonary exercise testing (max. CPET) provides the most accurate measurement of cardiorespiratory fitness. However, glioblastoma (GBM) patients often undergo less intensive tests, e.g., 6-min wa...
-
Article
Open AccessSarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients
Sarcopenia may complicate treatment in cancer patients. Herein, we assessed whether sarcopenia measurements derived from radiation planning computed tomography (CT) were associated with complications and tumor...
-
Article
Open AccessThe importance of considering competing risks in recurrence analysis of intracranial meningioma
The risk of recurrence is overestimated by the Kaplan–Meier method when competing events, such as death without recurrence, are present. Such overestimation can be avoided by using the Aalen-Johansen method, w...
-
Article
Open AccessALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma
Despite improvements in surgical as well as adjuvant therapies over the last decades, the prognosis for patients with glioblastoma remains poor. Five-Aminolevulinic acid (5-ALA) induced porphyrins are already ...
-
Article
Open AccessCorrection to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
-
Article
Open AccessFirst clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study
Following resection and standard adjuvant radio- and chemotherapy, approved maintenance therapies for glioblastoma are lacking. Intracavitary radioimmunotherapy (iRIT) with 177Lu-labeled 6A10-Fab fragments target...
-
Article
Open AccessUndetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and...
-
Article
Molecular predictors for decitabine efficacy in meningiomas – a pilot study
Effective chemotherapeutical agents for the treatment of meningiomas are still lacking. Previous in-vitro analyses revealed efficacy of decitabine (DCT), a DNA methyltransferase (DNMT) inhibitor established in...
-
Article
Open AccessConceptual development of an intensive exercise program for glioma patients (ActiNO): summary of clinical experience
Exercise proved to reduce cancer-related symptoms and prolong survival in some cancer types. However, brain tumor patients are often advised against strenuous exercise. Here, we summarize our experience with a...
-
Article
Open AccessThe use of radiosensitizing agents in the therapy of glioblastoma multiforme—a comprehensive review
Glioblastoma is the most common malignant brain tumor in human adults. Despite several improvements in resective as well as adjuvant therapy over the last decades, its overall prognosis remains poor. As a mean...
-
Article
5-ALA kinetics in meningiomas: analysis of tumor fluorescence and PpIX metabolism in vitro and comparative analyses with high-grade gliomas
Although the utility 5-aminolevulinic acid (5-ALA)-mediated fluorescence-guided surgery (FGS) in meningiomas is increasingly discussed, data about the kinetics of protoporphyrin IX (PpIX) and tumor fluorescenc...
-
Chapter
Fluorescence-Guided Resections: A Binary Approach to Surgery
Maximal tumor resection with negative margins plays a critical role in the surgical management of various types of cancer. However, delineation between healthy and tumorous tissue can be challenging. For this ...
-
Article
Behandlung von Gliomen - die neurochirurgische Perspektive
-
Article
Open AccessInitial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system
Primary angiitis of the central nervous system (PACNS) is a heterogeneous, rare, and poorly understood inflammatory disease. We aimed at non-invasive imaging of activated microglia/macrophages in patients with...
-
Chapter
Image-Guided Brain Surgery
In neurosurgery, the extent of resection plays a critical role, especially in the management of malignant gliomas. These tumors are characterized through a diffuse infiltration into the surrounding brain paren...
-
Article
Established and emerging uses of 5-ALA in the brain: an overview
5-aminolevulinic acid (5-ALA) was approved by the FDA in June 2017 as an intra-operative optical imaging agent for patients with gliomas (suspected World Health Organization Grades III or IV on preoperative im...
-
Article
5-ALA fluorescence-guided surgery of CNS tumors
-
Article
5-ALA and FDA approval for glioma surgery
The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan®; photonamic GmbH and Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade glio...
-
Article
Fluorescence-guided surgery with aminolevulinic acid for low-grade gliomas
Fluorescence guided surgery has developed over the last 2 decades as a formidable augmentation strategy to promote maximal safe resection and diagnostic accuracy within gliomas. The majority of the literature ...
